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Introduction 
The premise of P4 medicine, shorthand for predictive, pre-
ventive, personalized and participatory medicine, is that dis-
eases result from perturbations of biological networks.
Disease-perturbed networks both cause and reflect the pro-
gression of a disease. Thus, diseases can be diagnosed, treated
and prevented by understanding and intervening in the net-
works that underlie health and illness. And this is exactly the
prevailing view on infectious diseases. Infections can be con-
sidered as the result of the interplay between two complex
biological networks: the host and the pathogen. The under-
standing of this interaction requires large-scale analysis of
the host–pathogen interface. This knowledge should help to
identify host pathways important for infection as well as
pathogen determinants involved in disease progression. The
identified host and pathogen targets may help to develop
innovative therapies based on the modulation of the
host–pathogen interface. This short review establishes the
conceptual bases and discusses the principal aspects of P4
medicine in the framework of infectious diseases. 
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Infection systems biology: from reactive to
proactive (P4) medicine
Summary. This short review establishes the conceptual bases and discusses the principal aspects of P4—shorthand for pre-
dictive, preventive, personalized and participatory medicine—medicine, in the framework of infectious diseases. P4 medicine
is a new way to approach medical care; instead of acting when the patient is sick, physicians will be able to detect early warn-
ings of disease to take early action. Furthermore, people might even be able to adjust their lifestyles to prevent disease. P4
medicine is fuelled by systems approaches to disease, including methods for personalized genome sequencing and new com-
putational techniques for building dynamic disease predictive networks from massive amounts of data from a variety of
OMICs. An excellent example of the effectiveness of the P4 medicine approach is the change in cancer treatments. Emphasis
is placed on early detection, followed by genotyping of the patient to use the most adequate treatment according to the genetic
background. Cardiovascular diseases and perhaps even neurodegenerative disorders will be the next targets for P4 medicine.
The application of P4 medicine to infectious diseases is still in its infancy, but is a promising field that will provide much ben-
efit to both the patients and the health-care system. [Int Microbiol 2012; 15(2):55-60]
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Systems biology, health and disease 
Due to the enormous complexity of human biology, medical
research has historically followed a reductionist strategy,
which attempts to explain complex phenomena by defining
the functional properties of the individual elements that make
up the system. Thus, research focus went progressively from
the organism as a whole (anatomy), to the organs (physiolo-
gy), cells (cellular biology) and, more recently, molecules
(genes, proteins, lipids and metabolites, i.e., molecular biol-
ogy). This reductionist strategy assumes that the world that
surrounds us can be understood in terms of the properties of
its constituting parts by decomposing Nature into its simplest
parts and laws.
One must admit that this strategy has been extraordinari-
ly successful. Not only has it led to the discovery of the inti-
mate nature of the cellular and molecular structure of human
biology, but it has also resulted in dramatic advances in clin-
ical practice in all its specialties. Reductionism, however, has
its limits: it is not able to explain all phenomena, especially
those that involve more than one source and require the coor-
dinated function of different structures (systems), infectious
diseases being a clear example. It has become obvious that
only rarely biological functions can be attributed to individ-
ual molecules. In contrast, most biological systems, in health
as well as in disease, arise from complex interactions among
the numerous components of cells, such as proteins, DNA,
RNA and small molecules. Research in molecular biology
over the last forty years has revealed the nature and profound
complexity of biological systems. Such a complexity cannot
be understood by studying isolated genes and proteins indi-
vidually [3,4]. In fact, biological systems should be studied
as an integrated whole [3,4].
An alternative to the reductionist mindset is the perspec-
tive based on the “system”, interpreted as a group of individ-
ual components with emerging properties that cannot be
attributed to any single element on its own. Systems biology
is a new interdisciplinary field of research in which the inter-
actions among its components—both internal and external—
that influence biological processes are formulated with math-
ematical expressions. Systems biology was conceived to
manage the complexity observed in biological systems in a
quantitative and modelled manner. This holistic approach
allows us to comprehend the functions of biological systems
(processes) and thoroughly research how their interactions,
both internally and with other systems, result in the appear-
ance of new emerging properties. Therefore, the construction
of predictive models of the networks and dynamic interac-
tions between the biological components is essential and
should be based on the integration of high-throughput
OMICs data (transcriptomics, proteomics, metabolomics,
lipidomics, etc.). Through iterative rounds of model develop-
ment, testing, and filling in the gaps with experimental data,
models are refined to provide predictions that can ultimately
be used to help identify therapeutic targets and improve clin-
ical outcomes.
Infection as a result of host–pathogen
interplay 
Infection can be viewed as a consequence of specific interac-
tions between microbial pathogens and host cells. Critical
host cell components include receptors that allow viral and
bacterial attachment to, and eventually entry into, a target
cell. Host cell receptors may also be crucial in sensing bacte-
rial and viral molecules or patterns to activate early (i.e.,
innate) host cell responses [22,23,32]. While investigations
of virulence-associated factors on the pathogen side have
progressed over the years, few comprehensive studies have
analyzed the host–pathogen interplay. It is already accepted
that host cell factors are essential in infectious processes. In
addition, it has been shown, in many cases, both in vitro and
in living animals carrying specific genetic defects, that the
absence of critical host cell functions can either prevent or
enhance infection.
Pathogens rely on the coordinated action of virulence fac-
tors to colonize the host and to evade or subvert the subse-
quent immune response [12,17,19,29]. Classical examples
using intestinal microorganisms demonstrate that bacteria
trigger cytoskeletal changes at the host cell plasma mem-
brane to promote invasion and in most cases this is due to
modulation of the activation status of small GTPases [9,10].
Actin cytoskeleton dynamics are important not only during
virus assembly but also for virus internalization via endocy-
tosis. During infection, microbes also encounter locally resi-
dent as well as recruited phagocytic cells, including neutro-
phils, macrophages and dendritic cells [12,17,28,29]. These
cells are equipped with a variety of receptors that detect the
presence of invading microbes which may lead to phagocyte
maturation, synthesis of antimicrobial molecules and phago-
cytosis [12,13,14,17,29]. Consequently, pathogens use differ-
ent strategies to counteract phagocytes [8,12–14,17,28]. 
To avoid detection by pathogen recognition receptors
(PRRs), microorganisms have evolved ways of altering the
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molecules recognized by these receptors [24]. A key strate-
gy employed by viruses is to inhibit PRR signalling to pre-
vent interferon induction. For example, respiratory syncytial
virus encodes proteins blocking “toll-like” receptors (TLR)
3, 7 and 9-dependent signalling [30]. Many pathogens,
either viruses or bacteria, also control the cell death path-
way. This is crucial for the outcome of infection, not only in
terms of the ability of the pathogen to avoid destruction but
also with respect to how the infected cell communicates to
the immune system. In general, viruses either accelerate or
inhibit the cell death pathways, depending on the biology of
the specific virus [6]. As viruses do, obligate intracellular
pathogens generally suppress apoptotic death. Because this
death is less inflammatory than cytotoxic death, many non-
obligate intracellular bacteria use this strategy to neutralize
host cells.
The invasion of host cells by microbial pathogens is gen-
erally associated with the activation of NF-κB, mitogen-acti-
vated protein kinases (MAPKs) and interferon regulatory
factor (IRF) signalling pathways inducing the transcription of
genes coding for a variety of inflammatory mediators and
interferons. For many microorganisms, activation of these
responses leads to clearance of the infection. Not surprising-
ly, these responses are normally counteracted by pathogens
by, for example, the injection of proteins into the cell cytosol
to quench them [12,17,29]. Also many viral pathogens sub-
vert the activation of inflammatory signalling pathways by
blocking the activation of the intracellular receptors sensing
nucleic acids [15,31]. Finally, evidence indicates that micro-
bial pathogens may also modulate chromatin structure to
control the activation of host responses. In some cases, caus-
ing chromatin injury can be a strategy to take control of
major cellular functions including the cell cycle. In other
cases, manipulation of chromatin structure at specific
genomic locations by modulating epigenetic information
provides a way for the microbe to impose its own transcrip-
tional signature onto cells [2,16,26,27]. This is an emerging
field largely unexplored.
Systems biology of microbial infections
Several strategies combining bioinformatics with transcrip-
tomics, chemical genetics and functional genomics have
been used to identify host factors essential for pathogen
entry, survival, and replication. Nevertheless, the application
of systems biology to microbial infections is still in its infan-
cy and data mostly pertain to a few human infections.
However, the technologies, computational methods, and
genome information needed to successfully implement this
approach already exist. Technologies such as next-generation
sequencing have opened the door to sequencing total tran-
scriptomes. Proteomic technologies are evolving rapidly,
with throughput and sensitivity approaching that of microar-
rays. Metabolomics, glycomics, lipidomics, and phosphopro-
teomics are comparatively underdeveloped, but improve-
ments are certainly expected. In this context, it is not surpris-
ing that most of the studies have focused on transcriptomics
and functional genomics.
Transcriptomics. cDNA microarrays have been used to
determine the effects of pathogens on host-cell gene expres-
sion or in tissues upon animal infection. In many cases, the
responses induced by wild type strains and isogenic mutants
lacking known virulence factors have been compared. These
studies have addressed questions such as which are the gene
expression programmes induced by pathogens, how viru-
lence factors modify these programmes and the contribution
of the PRRs to the induction of the programmes. One of the
main conclusions of all these studies is that there is a com-
mon host response associated to infection, the so-called
“alarm signal” [18]. Data show that many of the gene clus-
ters targeted by microbial pathogens belong to the “alarm
signal” [15,28]. To understand the full complexity of the
host–pathogen interaction it is necessary the use of arrays
containing probes to both human (animal, plants) and micro-
bial genes to monitor simultaneously gene expression of both
host and pathogen.
Functional genomics. With the advent of the RNA
interference (RNAi) technology and its improvement over
the last decade, large-scale reverse genetic screens have
become feasible in model organisms and now also in human
cells [5]. RNAi allows to downregulate (or silence) expres-
sion of specific genes by introducing double-stranded RNA
(dsRNA) with sequence-complementarity to the target-
mRNA. To avoid induction of interferon- or other unspecific
responses to long dsRNA, small interfering dsRNAs
(siRNAs) directly or small hairpin RNAs (shRNAs) are used
for mammalian cells. In the context of host–pathogen inter-
play, loss-of-function screens using RNAi may uncover host
factors that are restrictive (host resistance factors, HRFs; e.g.,
silencing these factors enhances pathogen replication), or
permissive host factors (host susceptibility factors, HSFs;
e.g., when these factors are silenced pathogen replication is
reduced). In general, siRNA screens are prone to yield false
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positives due to off-target siRNA effects [11]. Therefore, hits
from primary screens should be validated using additional
siRNAs. The size of the primary hit list selected for this val-
idation depends on what stringency is chosen to filter the raw
screening data. For several recent arrayed genome-scale
siRNA-screens in human and in fruit fly cells (e.g., between
10,000 and >20,000 targets), the validated hit-list comprised
ca. 300 host factors [1,7,20,21,34]. Given the large number
of hits, basically all of the current host–pathogen interaction
studies originating from larger siRNA-screens resemble
proof-of-concept studies in that only a small subset of the hits
is usually selected for detailed functional characterization. 
A major issue affecting the application of systems biolo-
gy to microbial infections is the lack of integration of the
information obtained from a variety of omics which, in turn,
prevents the construction of predictive models. Moreover,
several rounds of biological perturbations (i.e., the use of
mutant pathogens, cellular siRNA knockdowns or knockout
mice) are required to produce a predictive model that could
be effectively utilized by the general infectious disease com-
munity. In fact, in most cases, researchers do not attempt to
validate the information obtained in vitro using suitable
infection models.
P4 infectious diseases medicine 
The term “P4 medicine” (personalized, predictive, preventive
and participatory medicine) was coined by David Galas and
Leroy Hood from the Institute for Systems Biology (ISB) in
Seattle. The ISB studies biological complexity based on three
fundamental premises: (i) there are two types of biological
information, i.e., digital genome information and environ-
mental information, outside the genome, that modifies the
above-mentioned digital information; (ii) biological informa-
tion is captured, processed, integrated and transferred by
means of biological networks (RNA, proteins, controlling
regions of the genes and small molecules) to the molecular
systems that execute vital functions; and (iii) biological
information is codified in a multi-scale hierarchy: DNA,
RNA, proteins, interactions, biological networks, tissues and
organs, individuals and, finally, ecologies. It is important to
highlight that the environment affects each level of this hier-
archy and modulates the reception of the digital information
from the genome. 
Let us consider the four “P” of P4 medicine in the context
of infectious diseases:
Personalized. It is said that P4 medicine will be “person-
alized” because it will be based on the genetic information of
each individual including the infecting microbial pathogen.
However, this would not be of much help without functional
studies to validate the genomic information. A very elegant
example is the study by Lalita Ramakrishnan and co-workers
reporting a locus associated to differential production of an
anti-inflammatory product leading to hypersusceptibility to
tuberculosis and leprosy [33]. On the other hand, it is techno-
logically feasible to analyze host responses to different infec-
tions ex vivo by challenging blood cells in a test tube. These
data could be compared to those obtained from infected
patients and even connected to different genotypes.
Altogether, this information will help to predict susceptibili-
ty to certain infections or whether the defence response will
be enough to clear the pathogen. The pathogen side is easier
to tackle. There are platforms allowing the identification of
the pathogen without culturing, the detection of virulence
factors associated to bad prognosis, and even the characteri-
zation of antibiotic-resistance markers. 
Predictive. Medicine will be “predictive” because this
personalized information will allow to determine the risk for
certain diseases in each individual. For example, certain gene
deficiencies can predispose to recurrent infections (for a
review see [25]). These are extreme cases but it is obvious
that not everybody is equally susceptible to infections. On
average, each human differs from another by less than one
percent of their genetic makeup. But these genetic differ-
ences give rise to our physical differences, including our
potential predisposition to various diseases. Health might be
the combination of two types of defence mechanisms against
infections: resistance and tolerance. Immunology has largely
focused on the identification of mechanisms of resistance,
but the molecular bases of tolerance are largely unknown.
Nevertheless, plotting health (cytokine levels, biomarkers,
fever, etc.) versus pathogen loads over the course of an infec-
tion may help to predict recovery and point out bifurcations
(failure of treatment). The slope of this plot defines the toler-
ance of the individual.
Preventive. Medicine will be “preventive” because, given
the prediction of risk, prophylactic measures (lifestyle or
therapeutic) will be able to decrease risk. In this context, it is
widely accepted that vaccination is the most efficient
approach to prevent infectious disease progression and may
even lead to eradication of the infection.
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Participatory. It will be “participatory” because many of
these prophylactic interventions will require the participation
of the patient. This includes a variety of aspects of participa-
tion such as sharing data, educating patients and physicians
and engaging patients in personal choices related to illness
and well-being. The increasing uses of social networks by
patients, as well as the activities exerted by patients’ associa-
tions are examples of participatory actions. However, there
are still technical problems for mining, comparing and ana-
lyzing data sets from thousands of millions of individuals.
Issues related to data ownership (by scientists and by institu-
tions) and a reluctance to believe in open-source and open-
data policies will have to be overcome if we are to mine the
incredible potential of the exploding opportunities of patient
data accumulation.
Theoretically, P4 infectious diseases medicine should
provide much benefit to both the patient and the health-care
system (Table 1). Among its advantages are: (i) the possibil-
ity of acquiring and processing data for each particular
host–pathogen interaction; (ii) the compilation and analysis
of longitudinal information for each individual, which would
enable early disease detection and monitor the therapeutic
effectiveness of established treatments; (iii) the stratification
of patients into disease groups to better defined clinical phe-
notypes hence leading to the development of alternative ther-
apies specifically directed at those phenotypes, thus achiev-
ing greater success rates; and (iv) the facilitation of the entire
drug development process by identifying new therapeutic tar-
get hubs, reducing adverse reactions to medication and
reducing time, cost and failure rate of therapeutic assays. 
However, new advances are still necessary for P4 infec-
tious disease medicine to become a reality, including: (i)
microfluidic techniques, analysis of individual cells and
molecular imaging; (ii) identification and validation of
organ-specific protein, micro RNA and other molecular bio-
markers; and (iii) new mathematical and computational
methods such as dynamic networks enabling the study of the
perturbations caused by treatments in biological networks.
Finally, the entire healthcare industry (from pharmaceutical
companies to healthcare providers, insurance companies and
medical diagnostic laboratories) will have also to carry out
major changes in the years to come, possibly favoring the
creation of global strategic alliances between academics,
industry and administrations in order to facilitate and cat-
alyze the arrival and development of P4 medicine.
Conclusions and future perspectives
The scientific advances and technological breakthroughs of
the last few decades, together with the birth of the new sci-
ence of complex systems and networks, have prepared the
ground for the birth and development of a new way to handle
infectious diseases: P4 medicine. This short review justifies
this possibility, while discussing its main advantages and cur-
rent limitations. For those sceptical readers who consider that
this is still far off and is confined, or nearly so, to the realm
of science fiction, I would like to remind them that just sev-
enteen years ago sequencing a bacterial genome was a daunt-
ing task and its achievement deserved the front page of
Science. Nowadays the same result does not merit even a full
length paper in a specialized journal. On the whole, despite
the fascinating technical problems ahead, P4 medicine shows
great promises to maximize wellness for each individual
rather than simply to treat infections. The future is just
around the corner! 
P4 INFECTION DISEASE MEDICINE
Table 1. Benefits of P4 infectious diseases medicine
Evidence-based medicine P4 medicine
Symptoms based Based on pre-symptomatic markers
Disease-treatment system Wellness-maintenance system
Few measurements Many measurements, including a variety of OMICs
Disease-centric Individual-centric
No large-scale diffusion of medical information Social networking of patients to enhanced shared experiences and diffusion
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